PRIMARY STUDY
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Key Findings: Compared with placebo, THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function, although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin and increased glucose-dependent insulinotropic peptide. THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 62
Study Result: Positive
Research Location(s): Bhutan, United Kingdom
Year of Pub: 2016
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Dosage: Subjects were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks.
Citation: Jadoon KA, et al. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016; 39:1777-86. doi: 10.2337/dc16-0650
Authors: Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD
